by avrobio | Aug 2, 2016 | Press Release
Company Leverages Disruptive Therapies to Create New Paradigms in the Treatment of Fabry Disease and Acute Myeloid Leukemia Cambridge, MA, August 2, 2016 – AVROBIO, Inc, a clinical-stage biotechnology company developing transformative, life-changing gene therapies for...
by avrobio | May 13, 2016 | Press Release
May 13, 2016 Cambridge, MA May 13, 2016 – AVROBIO, a clinical-stage biotechnology company developing transformative, life-changing gene therapies targeting rare diseases and cancer, today announced it has been awarded lab space at Johnson & Johnson’s (J&J)...
by avrobio | Feb 18, 2016 | Press Release
Disruptive Therapies with Potential to Displace Standard of Care Treatments for Acute Myeloid Leukemia (AML) and Fabry Disease Announces Management Team of Industry Leaders with Unmatched Scientific, Business and Manufacturing Expertise in Cell and Gene Therapies and...
